Compare NTLA & EQBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | EQBK |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 986.9M | 870.8M |
| IPO Year | 2016 | 2015 |
| Metric | NTLA | EQBK |
|---|---|---|
| Price | $10.75 | $46.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 6 |
| Target Price | $19.83 | ★ $47.80 |
| AVG Volume (30 Days) | ★ 3.6M | 81.2K |
| Earning Date | 02-26-2026 | 01-21-2026 |
| Dividend Yield | N/A | ★ 1.54% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.00 |
| Revenue | $57,528,000.00 | ★ $186,035,000.00 |
| Revenue This Year | $1.96 | $15.54 |
| Revenue Next Year | N/A | $37.88 |
| P/E Ratio | ★ N/A | $46.53 |
| Revenue Growth | ★ 33.52 | 17.93 |
| 52 Week Low | $5.90 | $34.11 |
| 52 Week High | $28.25 | $48.14 |
| Indicator | NTLA | EQBK |
|---|---|---|
| Relative Strength Index (RSI) | 61.75 | 63.69 |
| Support Level | $8.94 | $44.46 |
| Resistance Level | $9.62 | $46.99 |
| Average True Range (ATR) | 0.46 | 1.23 |
| MACD | 0.28 | -0.06 |
| Stochastic Oscillator | 89.42 | 67.31 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.